Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics - 1 Oct 2020

Schneider Susanne A, Hizli Baccara, Alcalay Roy N

Abstract excerpt

In recent years, a precision medicine approach, which customizes medical treatments based on patients' individual profiles and incorporates variability in genes, the environment, and lifestyle, has transformed medical care in numerous medical fields, most notably oncology. Applying a similar approach to Parkinson's disease (PD) may promote the development of disease-modifying agents that could help slow...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deep Brain Stimulation

Share to Genetic Predisposition to Disease

Share to Genetic Therapy

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Parkinsonian Disorders

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 32914362
DOI: 10.1007/s13311-020-00920-8
PMCID: PMC7483040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism.PMID 32914362Read ↗

Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease.Semantic proximity Read ↗

Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.Semantic proximity Read ↗

The genetic background of Parkinson's disease and novel therapeutic targets.Semantic proximity Read ↗

Precision medicine for Parkinson’s disease: The subtyping challengeSemantic proximity Read ↗

GBA1-and LRRK2-directed Treatments: The Way Forward.Semantic proximity Read ↗

New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin.Semantic proximity Read ↗

An update on the monogenic causes of Parkinson's disease: Impact on patient stratification and personalised medicine.Semantic proximity Read ↗

The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson's Disease.Semantic proximity Read ↗

Bridging Genetics and Precision Medicine in Parkinson’s Disease through GP2Semantic proximity Read ↗

Genetics of Parkinson's Disease: From Causes to Treatment.Semantic proximity Read ↗

Disease‑Modifying Therapies for Parkinson’s Disease: Biological Mechanisms, Pharmacological Strategies, and Clinical PipelineSemantic proximity Read ↗

GBA-associated PD: chances and obstacles for targeted treatment strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.